For: | Zhang CY, Liu S, Yang M. Regulatory T cells and their associated factors in hepatocellular carcinoma development and therapy. World J Gastroenterol 2022; 28(27): 3346-3358 [PMID: 36158267 DOI: 10.3748/wjg.v28.i27.3346] |
---|---|
URL: | https://www.wjgnet.com/1948-5182/full/v28/i27/3346.htm |
Number | Citing Articles |
1 |
Zachary J. Brown, Samantha M. Ruff, Timothy M. Pawlik. The effect of liver disease on hepatic microenvironment and implications for immune therapy. Frontiers in Pharmacology 2023; 14 doi: 10.3389/fphar.2023.1225821
|
2 |
Chunye Zhang, Yuxiang Sui, Shuai Liu, Ming Yang. In vitro and in vivo experimental models for cancer immunotherapy study. Current Research in Biotechnology 2024; 7: 100210 doi: 10.1016/j.crbiot.2024.100210
|
3 |
Pietro Guerra, Andrea Martini, Patrizia Pontisso, Paolo Angeli. Novel Molecular Targets for Immune Surveillance of Hepatocellular Carcinoma. Cancers 2023; 15(14): 3629 doi: 10.3390/cancers15143629
|
4 |
Kah Ming Wong, Yong Hui Wong, Sau Har Lee. In Silico Discovery of LL13, a Shortened Pardaxin 6 Peptide Derivative with Anti-proliferative Activity. International Journal of Peptide Research and Therapeutics 2024; 30(4) doi: 10.1007/s10989-024-10615-9
|
5 |
Lien-Hung Huang, Cheng-Shyuan Rau, Yueh-Wei Liu, Chia-Jung Wu, Peng-Chen Chien, Hui-Ping Lin, Yi-Chan Wu, Chun-Ying Huang, Ting-Min Hsieh, Ching-Hua Hsieh. Exploring the Regulatory Role of XIST-microRNAs/mRNA Network in Circulating CD4+ T Cells of Hepatocellular Carcinoma Patients. Biomedicines 2023; 11(7): 1848 doi: 10.3390/biomedicines11071848
|
6 |
Alexsis Garcia, Stephen O. Mathew. Racial/Ethnic Disparities and Immunotherapeutic Advances in the Treatment of Hepatocellular Carcinoma. Cancers 2024; 16(13): 2446 doi: 10.3390/cancers16132446
|
7 |
Chunye Zhang, Yuxiang Sui, Shuai Liu, Ming Yang. Molecular mechanisms of metabolic disease-associated hepatic inflammation in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Exploration of Digestive Diseases 2023; : 246 doi: 10.37349/edd.2023.00029
|
8 |
Atieh Pourbagheri‐Sigaroodi, Majid Momeny, Nima Rezaei, Fatemeh Fallah, Davood Bashash. Immune landscape of hepatocellular carcinoma: From dysregulation of the immune responses to the potential immunotherapies. Cell Biochemistry and Function 2024; 42(5) doi: 10.1002/cbf.4098
|
9 |
Gaocheng Wang, Jingjing Wang, Shuilin Dong, Zhanguo Zhang, Wanguang Zhang, Jianping Zhao. Immune checkpoint inhibitor‑associated diabetes mellitus in patients with HCC: Report of three cases and literature review. Experimental and Therapeutic Medicine 2024; 27(5) doi: 10.3892/etm.2024.12486
|
10 |
Ming Yang, Ethan Vanderwert, Eric T. Kimchi, Kevin F. Staveley-O’Carroll, Guangfu Li. The Important Roles of Natural Killer Cells in Liver Fibrosis. Biomedicines 2023; 11(5): 1391 doi: 10.3390/biomedicines11051391
|
11 |
Xize Wu, Changbin Yuan, Jiaxiang Pan, Yi Zhou, Xue Pan, Jian Kang, Lihong Ren, Lihong Gong, Yue Li. CXCL9, IL2RB, and SPP1, potential diagnostic biomarkers in the co-morbidity pattern of atherosclerosis and non-alcoholic steatohepatitis. Scientific Reports 2024; 14(1) doi: 10.1038/s41598-024-66287-4
|
12 |
Zhanao He, Jie Zhang, Wukui Huang. Diagnostic role and immune correlates of programmed cell death-related genes in hepatocellular carcinoma. Scientific Reports 2023; 13(1) doi: 10.1038/s41598-023-47560-4
|
13 |
Chun-Ye Zhang, Shuai Liu, Ming Yang. Treatment of liver fibrosis: Past, current, and future. World Journal of Hepatology 2023; 15(6): 755-774 doi: 10.4254/wjh.v15.i6.755
Abstract(642) |
Core Tip(585) |
Full Article(HTML)(4239)
|
Full Article with Cover (PDF)-4268K(77)
|
Full Article (Word)-1195K(33)
|
Audio-303K(2)
|
Peer-Review Report-179K(48)
|
Answering Reviewers-123K(39)
|
Full Article (PDF)-1940K(381)
|
Full Article (XML)-339K(44)
|
Times Cited (20)
|
Total Visits (7726)
|
Open
|
14 |
Xinyan Wu, Zhigang Zhou, Qiang Cao, Yuquan Chen, Junling Gong, Qi Zhang, Yi Qiang, Yanfeng Lu, Guangzhu Cao. Reprogramming of Treg cells in the inflammatory microenvironment during immunotherapy: a literature review. Frontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1268188
|
15 |
Yusra Zarlashat, Shakil Abbas, Abdul Ghaffar. Hepatocellular Carcinoma: Beyond the Border of Advanced Stage Therapy. Cancers 2024; 16(11): 2034 doi: 10.3390/cancers16112034
|
16 |
Lingzhen Hu, Zongren Wang, Yang Liao, Xiaomeng Jiang, Huojun Lian, Zhuoying Lin. Tumor-infiltrating T-Lymphocyte immunity-related immune tolerance and anti–programmed cell death protein 1/ligand of programmed cell death protein 1 therapy for advanced hepatocellular carcinoma. Oncology and Translational Medicine 2024; 10(4): 162 doi: 10.1097/ot9.0000000000000041
|
17 |
Mona Abd El-Rahman Abu El-Makarem, Douaa Mohammed Sayed, Ragaa Abdelshaheed Matta, Mahmoud Ragab Mohamed, Manal Ameer Abd El-Malak, Nehal Ibrahim Abbas. Interaction of peripheral CD4+CD25+CD127− Tregs with prolactin in HCV hepatocellular carcinoma: oncogenic or immunogenic mechanisms. Egyptian Liver Journal 2023; 13(1) doi: 10.1186/s43066-023-00250-2
|
18 |
Chunye Zhang, Yuxiang Sui, Shuai Liu, Ming Yang. The Roles of Myeloid-Derived Suppressor Cells in Liver Disease. Biomedicines 2024; 12(2): 299 doi: 10.3390/biomedicines12020299
|